Wettig Thane, CEO of an undisclosed company, has demonstrated a clear buying bias in recent insider transactions, with $179,882 in total purchases compared to $111,860 in sales across 23 trades involving two stocks: FGEN and KYNB. The majority of activity has centered on FibroGen (FGEN), where Thane executed multiple purchases, including a $95,470 acquisition on March 7, 2024, and a $50,663 buy on March 24, 2025. Smaller but consistent FGEN purchases occurred quarterly, such as a $2,683 acquisition on June 6, 2024, and a $1,926 buy on June 6, 2025. More recently, Thane expanded holdings into KYN Biosciences (KYNB), acquiring $1,894 in shares on March 6, 2026.
Notably, Thane’s selling activity has been minimal, with no disposals in the most recent filings. The largest sale was a $55,671 transaction in FGEN on February 1, 2024, followed by sporadic smaller sales, including a $3,000 trade on September 6, 2025. The pattern suggests a long-term accumulation strategy, particularly in FGEN, with recent diversification into KYNB. Transaction frequency and dollar values indicate sustained confidence in these holdings, with purchases outweighing sales by nearly $68,000 overall. The absence of recent disposals further reinforces this directional bias.
AI-assisted summary